Alcobra Ltd. (NASDAQ:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity …
Two drugs directed at behavioral disorders failed mid-stage studies on Wednesday morning, said sponsors Alcobra Ltd (NASDAQ:ADHD) and Transition Therapeutics Inc (USA) (NASDAQ:TTHI), yet …
Himax Technologies, Inc. (ADR) (NASDAQ:HIMX) shares increased 4.
Alcobra Ltd (NASDAQ:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit …
Alcobra Ltd (NASDAQ:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity …
In a research note released today, Roth Capital research team, led by analyst Debjit Chattopadhyay, maintained a Buy rating on Alcobra Ltd (NASDAQ:ADHD) with a $10 price …
Roth Capital analyst Debjit Chattopadhyay was out pounding the table on Alcobra Ltd (NASDAQ:ADHD) Tuesday, reiterating a Buy rating and a price target …
Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit …
Alcobra Ltd. (Nasdaq:ADHD) today reported that it has closed its previously announced public offering of ordinary shares.
